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presence or dosage of fermentedObjective: Fermented formulae (FERM) and a specific mixture of 90% short-
chain galacto-oligosaccharides and 10% long-chain fructo-oligosaccharides
(scGOS/lcFOS; 9:1) have a potential beneficial effect on gastrointestinal func-
tion and microbiota development in infants. The present study assessed the safety
and tolerance of the combination of partly fermented infant milk formulae and
scGOS/lcFOS compared with either 1 feature, in healthy term infants.
Methods: Four hundred thirty-two infants were enrolled before 28 days of
age and followed up to 17 weeks of age and assigned to 1 of the 4 groups: (i)
formula with scGOS/lcFOS, (ii) scGOS/lcFOSþ 15% FERM, (iii) scGOS/
lcFOSþ 50% FERM, or (iv) 50% fermented formula (50% FERM). Primary
outcome was daily weight gain during intervention (equivalence criterion:
difference in daily weight gain3 g/day). Infants’ anthropometrics, formula
intake, number, and type of (serious) AEs were monitored monthly. Stool
samples were collected at baseline and after 17 weeks for analysis of
physiological and microbiological parameters.
Results: Equivalence of weight gain per day was demonstrated in both the
intention-to-treat and per-protocol population, with a mean weight gain (SD)
of 29.7 (6.1), 28.2 (4.8), 28.5 (5.0), and 28.7 (5.9) g/day for the groups i to iv
respectively. No differences were observed in other growth parameters,
formula intake, and the number or severity of AEs. In all scGOS/lcFOS-
containing formulae, a beneficial effect of scGOS/lcFOS was observed,
indicated by the lower pH, lower Clostridium difficile levels, and higher
secretory immunoglobulin A levels.
Conclusions: The partly fermented infant milk formulae containing the
specific mixture scGOS/lcFOS were well-tolerated and resulted in normal
growth in healthy infants.
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Huet et al JPGN  Volume 63, Number 4, October 2016Early nutrition plays an important role in the development
and functioning of the gastrointestinal (GI) tract (4,5). Histori-
cally, fermented and/or acidified infant milk formulae have been
used to promote digestibility and tolerance of formula. Only
limited clinical evidence is, however, available to substantiate
these suggested health benefits (6–10). Fermented formulae may
reduce frequency and severity of gut discomfort (8), reduce the
severity of infectious diarrhea, that is, fewer cases of dehydration
or medical consultation (9) and stimulate the presence of intes-
tinal bifidobacteria in healthy young infants (10). The ESPGHAN
Committee on Nutrition, based on the limited evidence,
cautiously reported that no safety concerns are expressed for
the use of fermented formulae, although they emphasized more
studies are warranted (7).
The development and maturation of the GI tract is
accompanied by the dynamic enteric process of microbiota
development, considered crucial for healthy infant development
(11). Early nutrition has a strong effect on microbiota develop-
ment: breast-fed infants typically have a microbiota dominated
by bifidobacteria, whereas nonprebiotic supplemented formula-
fed infants have a more diverse microbiota (12). Inspired by the
molecular size distribution of the nondigestible oligosaccharides
present in human milk (13), a specific mixture of 90% short-
chain galacto-oligosaccharides and 10% long-chain fructo-
oligosaccharides (scGOS/lcFOS; 9:1) was developed (14,15).
Formulae containing this specific prebiotic mixture were shown
to stimulate intestinal colonization with bifidobacteria resulting
in beneficial effects on immune function (16–18). The addition
of this prebiotic mixture prevents constipation, which is known
to be more common in formula-fed than breast-fed infants (19).
Safety and tolerance of formulae containing scGOS/lcFOS (9:1)
has been demonstrated in several studies, with respect to growth
(20–22) and digestive function (22–25). None of the studies
included the prebiotic mixture in combination with fermented
infant formula.
Supplementation of fermented formula with the specific
prebiotic mixture scGOS/lcFOS could have a complementary,
beneficial effect on the GI function of infants. First, the nutritional
safety and adequacy of this new nutritional concept should be
demonstrated following stringent evaluation (26–28).
In our study, safety was evaluated with daily weight gain as
primary outcome parameter, and in addition, length gain, head
circumference gain, and (serious) adverse events (AEs) were mon-
itored. As an exploratory outcome, fecal physiological and
microbial parameters were evaluated to confirm the beneficial
effects of scGOS/lcFOS.
SUBJECTS AND METHODS
Subjects
Subjects were healthy infants recruited from mothers who
could not or had chosen not to (continue to) breast-feed. Inclusion
criteria were gestational age between 37 weeks and 42 weeks,
birth weight between 2.5 and 4.5 kg, and postnatal age 28 days.
Infants were excluded from the study if they had a congenital
condition or illness that could interfere with the study or if they
had a known or increased risk for cow’s milk allergy. Other
exclusion criteria were maternal gestational diabetes, participa-
tion in another clinical trial or investigator’s uncertainty about the
willingness or ability of the parents to comply with the protocol
requirements.
The study was conducted according to ICH-GCP
principles, and in compliance with the principles of the
Declaration of Helsinki and with the local laws and regulations
of the country where the study was performed. All participatinge44centers obtained approval of their independent local Ethical
Review Board.
Written informed consent was obtained from all parent(s)/
guardian, ages 18 years or older, before enrolment to the study. This
trial was registered in the Dutch Trial Register (NTR 2521).
Participating Centers
The present study was conducted in a total of 24 study centers
in France (n¼ 7; CHU of Dijon, American Memorial Hospital in
Reims, CHU La conception in Marseille, CHU of Angers, CHU of
Besancon, and a private pediatrician clinic in Essey les Nancy and
in Floirac), Belgium (n¼ 10; UZ Brussel, Jessa Ziekenhuis Hasselt,
private practice in Asse, Sainte Elisabeth Clinique in Namur, Heilig
Hart Hospital in Roeleare, Aalsters Stedelijk Ziekenhuis in Aalst,
Imelda Hospital in Bonheiden, GZA Sint Augustinus in Wilrijk, AZ
Sint Blasius in Dendermonde, and AZ Sint Vicentius in Antwerp),
and Ireland (n¼ 7; 2 tertiary referral hospitals: Cork University
Hospital, National Maternity Hospital, Dublin, and 5 primary
care centers: Medical Center and The Palms surgeries in Gorey,
Meadowcroft Surgery in Wicklow, Slaney Medical Center in
Enniscorthy, and Town Hall Surgery in Bray).
Trial Design
The present study was a prospective, double-blind, con-
trolled, randomized, parallel-group, multicenter controlled equiv-
alence trial. Infants, whose parents intended to feed their infants
formula, were assigned to 1 of the 4 groups, using a computerized
random-number generator with sex and study site strata. Formulae
were coded by the sponsor and both the investigators and the
infant’s parents were blinded to the formula. Baseline measure-
ments were taken at enrolment and parents received the assigned
infant formula with written preparation instructions, were advised
to feed infants ad libitum, and were provided with recommen-
dations for product intake volumes depending on the infant’s
weight.
During the intervention period infants were to be fed ad
libitum exclusively with their allocated formula starting on the day
of enrolment (0–28 days of age) until 17 weeks of age. The study
consisted of a baseline visit and 4 subsequent hospital visits at 4, 8,
13, and 17 weeks of postnatal age. In addition, a follow-up phone
call was performed 2 weeks after the last study visit. Parents were
provided with diaries to record formula intake, GI symptoms,
crying, sleeping, and stool characteristics every day during the
week before the study visits. At each visit, investigators took
anthropometric measures, reviewed compliance (based on evalu-
ation of diaries), provided study product, and assessed the occur-
rence and outcome of (serious) AEs and use of concomitant
medication and nutritional supplements by open questioning and/
or diagnosis.
Furthermore, fecal samples were collected by the parents
either during or shortly after the baseline visit, and just before the
final visit at their infant’s age of 17 weeks for analysis of the fecal
physiological parameters and microbiological composition.
Study Formulae
Each formula was powdered infant formula providing com-
plete nutritional support for infants in the first 6 months of life. The
formulae were isocaloric and contained per 100 mL a similar
amount of 66 kcal energy, 1.35 g protein, 8.2–8.4 g carbohydrate,
3.0–3.1 g lipids, and vitamins and minerals according to Directive
2006/141/EC. The products varied only in the amount of formulawww.jpgn.org
TABLE 1. Composition of the intervention products (per 100 mL)
Per 100 mL scGOS/lcFOS scGOS/lcFOS þ15% FERM scGOS/lcFOS þ50% FERM 50% FERM
scGOS/lcFOS 9:1, g 0.8 0.8 0.8 –
Fermented formula

– 15% 50% 50%
Energy, kcal 66 66 66 66
Fat, g 3.0 3.0 3.0 3.1
Protein, g 1.35 1.35 1.35 1.36
Carbohydrates, g 8.2 8.2 8.2 8.4
15% FERM ¼ infant formula consisting of 15% fermented infant formula; 50% FERM ¼ infant formula consisting of 50% fermented infant formula;
scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-oligosaccharides.
Fermented by a specific combination of Bifidobacterium breve and Streptococcus thermophilus.
JPGN  Volume 63, Number 4, October 2016 Fermented Infant Formulae With scGOS/lcFOS Support Adequate Growthproduced by a specific fermentation process using Bifidobacterium
breve and Streptococcus thermophiles (this process is called Lac-
tofidus) and the presence of prebiotics, that is, 90% short-chain
galacto-oligosaccharides and 10% long-chain fructo-oligosacchar-
ides (0.8 g per 100 mL; Table 1). The fermentation process
(Lactofidus) is followed by mild heat treatment. In total, 4 formulae
were tested (i) a nonfermented commercially available formula with
prebiotics (scGOS/lcFOS), (ii) a formula containing 15% fermented
formula and prebiotics (scGOS/lcFOSþ 15% fermented formulae
[FERM]), (iii) a formula containing 50% fermented formula and
prebiotics (scGOS/lcFOSþ 50% FERM), and (iv) a commercially
available formula containing 50% fermented formula without pre-
biotics (50% FERM). Hence, formula ii, iii, and iv are composed of
a mixture of fermented and nonfermented infant formula in a ratio
of 15:85 (ii) or 50:50 (iii, iv). The rationale to supplement prebiotics
to a product with a level of 50% fermented formula was based on the
previously observed beneficial effects on gut comfort (8). The level
of 15% fermented formula was included to assess a potential dose
dependency given the unknown effect on safety and tolerance of the
newly developed formulae and has been shown to be well-tolerated
(29). All formulae had a similar taste, smell, and color and were
manufactured according to good manufacturing practices by Nutri-
cia (Steenvoorde, France). The study products were to be stored at
the sites at a secure and limited access storage area protected from
extremes of light, temperature, and humidity.
Measurements
The primary outcome was weight gain per day from study
entry to 17 weeks of age, that is, from 28 to 119 days of age. The
secondary outcomes were length, head circumference, and mid-
upper arm circumference. For safety assessment, the number, type,
and severity of AEs were monitored and the use of medication. In
addition, fecal physiological parameters and microbial composition
were studied.
At each visit, the mean weight for each infant was registered
by weighing them twice naked, on calibrated electronic scales, and
in case of >100 g deviation an additional measurement was
performed. The mean supine length of infants was registered by
measuring them twice using a standard measuring board, and in case
of >5 mm deviation an additional measurement was performed. A
nonstretchable slotted insertion tape was used to measure head
circumference in duplicate (or 3 times if deviation of >2 mm
between measurements). The repeated measures in 1 infant were
performed by the same investigator, if possible, using the same
equipment. In case a third measurement was required, the 2
measures closest together were averaged as outcome measurement.
Diaries, filled in by the parents during the 7-day period
before each visit, registered information on quantity of formulawww.jpgn.orgintake. In the feeding record, the number of feeds and the amount of
formula prepared and left over per feed was registered. During the
17-week study period, (serious) AEs were documented by the
investigators at each visit. Details recorded were start and stop
date of the event, its severity, and actions that were taken. More-
over, the investigators documented (probability of) any relation
with the study product.
Fecal Parameters
Stool samples were collected by parents and brought to the
study site for storage at or below –188C for a maximum of 4
months. Thereafter, the samples were transported to Nutricia
Research in insulated containers containing solid CO2 (dry ice)
and stored at –808C. Fecal parameters were determined for samples
of visit 1 (baseline) and visit 5 (end of intervention period) for each
study arm. Only samples of a subgroup of subjects were analyzed,
which had a complete set of stool samples (both visits) with
sufficient amount of stool for all analyses. In addition, samples
from infant that used any systemic antibiotics any time after birth or
that used thickeners added to formula during the study were
excluded from analyses.
In the selected set of fecal samples the effect of the infant
formulae was assessed on the following physiological and
microbial parameters: pH, short-chain fatty acid (SCFA) levels
(ie, acetate, propionate, butyrate, isobutyrate, valerate, and iso-
valerate), D- and L-lactate, secretory immunoglobulin A (SIgA),
calprotectin, and presence of Clostridium difficile. The quantifi-
cation methodology of these parameters have been described in
more detail previously (25,30,31), except for calprotectin and
presence of C. difficile. Human calprotectin levels in the stool
samples were quantified with the Bu¨hlmann Calprotectin ELISA
kit (Bu¨hlmann Laboratories AG, Scho¨nenbuch, Switzerland)
according to the manufacturer’s protocol. The presence of C.
difficile was detected with quantitative polymerase chain reaction
utilizing primers 16S-Cldif -F (50-GCA ACG CGA AGA ACC
TTA CCT A-30) and 16S-Cldif -R (50-GAA GGG AAC TCT CCG
ATT AAG GA-30) in conjunction with probe 16S-Cldif (50-VIC-
TGA CAT CCC AAT GAC A-NFQ-MGB-30), which is labeled
with the reporter dye VIC and with the quencher NFQ-MGB
(Applied Biosystems, Bleiswijk, The Netherlands). Genomic
DNA of C. difficile LMG 21717 was used for the standard curve.
The assay was performed with 1 TaqMan universal master mix
(Applied Biosystems), 0.4 mmol/L of both primers, 0.2 mmol/L
probe, and DNA extract in a final volume of 25 mL. The
amplification program included an initial denaturation step at
958C for 10 minutes, followed by 40 cycles of denaturation at
958C for 15 seconds and primer annealing and extension at 608C
for 60 seconds.e45
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During statistical analysis 3 comparisons of interest have
been investigated. The effect of fermented formula is assessed by
comparing scGOS/lcFOSþ 15% FERM and scGOS/lcFOSþ 50%
FERM groups with the scGOS/lcFOS group. The effect of prebiotic
addition is assessed by comparing the scGOS/lcFOSþ 50% FERM
group versus the 50% FERM group. The primary objective of the
study was to test for equivalence of weight gain using the predefined
margins of equivalence of 0.5 standard deviation (SD) of the
difference in weight gain per day from randomization until 17
weeks of age. We set a minimum of 3 g/day (28) and a maximum
value of 5 g/day for the equivalence margin to be used as clinically
relevant margins in case 0.5 SD was exceeding these margins. To
conclude equivalence, the 2-sided 90% confidence intervals for the
differences in mean weight gain should lie entirely between –0.5
SD and þ0.5 SD margins. This margin was also used to conclude
equivalence for length gain and head circumference gain. The
required sample size for 2 one-sided statistical testing using
a¼ 0.05 and a power¼ 0.80 was 70 infants per intervention group.
Allowing for a drop-out rate of 35%, a total of 432 infants (108 per
group) had to be enrolled. The equivalence analysis was performed
using parametric growth curves, this model describes the develop-
ment of growth parameters (ie, weight) over time by a second-order
polynomial curve correcting for sex, site was taken into account as a
random effect, and each subject’s intercept and slope were taken
into account as random effects. Sensitivity analyses to evaluate
robustness of results were performed using analysis of covariance
on the 17 weeks of age measurement with the randomization
measurement as covariate and a mixed model using the age variable
as a categorical variable. In addition, to compare the intervention
groups with the WHO Child Growth Standards of breastfed infants,
an analysis of growth parameter z scores using WHO growth
trajectories (32) were performed by using a mixed model with
adjustment of baseline z score. In any other analyses, for continuous
data 2 sample t tests were used and Wilcoxon rank sum tests (WR)
were used in case of violation of normality assumption and/or
presence of outliers. Categorical response parameters were ana-
lyzed by using Chi-square tests (C; Fisher exact tests [FEs] in case
sparse cells occurred). The statistical analysis was performed by
Nutricia Research using SAS (SAS Enterprise Guide 4.3 or higher)Subjects rand
(N = 432
scGOS/lcFOS
+ 15% FERM
(N = 111)  
Subjects intende
(N = 431
Analyzed ITT
(N = 111) 
Early withdrawals
(N = 42) 
Completed
(N = 69)
Analyzed
ITT (N = 109) 
Early withdrawals
(N = 34)
Completed
(N = 75)
Analyzed PP
(N = 79)
Analyzed PP
(N = 79)
scGOS/lcFOS
+ 50% FERM
(N = 109)   
FIGURE 1. Disposition of study subjects per intervention group. ASR ¼
intention-to-treat; PP ¼ per protocol; scGOS/lcFOS ¼ short-chain galacto
e46for Windows (SAS Institute Inc., Cary, NC). In the intention-to-
treat (ITT) analysis, the data of all infants, except for those
erroneously randomized were to be used. In the per-protocol
(PP) analysis, eligibility of data was assessed on visit level, that
is, a subject could be part of the PP population at baseline and visits
2 and 3, but excluded from the PP population at visits 4 and 5 if a
protocol violation occurred after visit 3. In case of major protocol
deviations, for example, if an inclusion criterion for birth weight
was not met or lack of postbaseline visits, complete subjects were
excluded from the PP dataset. Fecal composition data were eval-
uated using SigmaStat Statistical Analysis Software (Systat Soft-
ware Inc., San Jose, CA). If<30% of the values were below limit of
detection (BLD) or—in case of the quantitative polymerase chain
reaction assays—not quantifiable (NQ), the value BLD was
replaced by (detection limit/2) and the value NQ was replaced
by (detection limitþ limit of quantification)/2, after which WRs
were performed. If >30% of the values were BLD or NQ, value
BLD was replaced by ‘‘0’’ and the other values (including ‘‘NQ’’)
were replaced by ‘‘1,’’ after which P values were calculated using
Chi-square test to assess differences in prevalence of the
corresponding parameter.
RESULTS
Subject Characteristics
From the total of 432 randomized subjects, included between
October 2010 and September 2012, 16 subjects were excluded from
the all-subjects-treated (AST) population because they did not
consume any study product. One subject was diagnosed with
hypothyroidism and was considered as not healthy, erroneously
randomized, and excluded from ITT analysis (Fig. 1). A total of 276
subjects completed the study until 17 weeks of age, whereas 155
(36%) subjects dropped-out from the study prematurely. The num-
ber of subjects that completed the study was not apparently different
between groups, although the number tended to be higher in the
group combining scGOS/lcFOS with 50% FERM compared to that
with 50% FERM only (FE P¼ 0.091). The most common reason for
drop-out was an (serious) AE (n¼ 72), other reasons were with-
drawal of informed consent (n¼54), lost to follow-up (n¼ 15),
protocol violation (n¼ 1), or other reasons (n¼ 13). There were no
differences in reasons for drop-out between groups. At baseline, noomized
)  
d to treat
)  
50% FERM
(N = 107)
Completed
(N = 61)
Early withdrawals
(N = 46)
Analyzed ITT
(N = 107) 
Completed
(N = 71)
Early withdrawals
(N = 33)
Analyzed ITT
(N = 104) 
Analyzed PP
(N = 65)
Analyzed PP
(N = 75)
scGOS/lcFOS
(N = 104)
all subjects randomized; FERM ¼ fermented infant formula; ITT ¼
-oligosaccarides and long-chain fructo-oligosaccharides.
www.jpgn.org
TABLE 2. Demographics and baseline characteristics of infants per intervention group of the per protocol population (n¼298)
Statistic
scGOS/lcFOS
(N¼ 75)
scGOS/lcFOS þ15% FERM
(N¼ 79)
scGOS/lcFOS þ50% FERM
(N¼ 79)
50% FERM
(N¼ 65)
Sex F
Male n (%) 39 (52.0%) 37 (46.8%) 39 (49.4%) 33 (50.8%)
Female n (%) 36 (48.0%) 42 (53.2%) 40 (50.6%) 32 (49.2%)
Mode of birth F
Natural n (%) 61 (81.3%) 60 (75.9%) 58 (73.4%) 52 (80.0%)
C-section n (%) 14 (18.7%) 19 (24.1%) 21 (26.6%) 13 (20.0%)
Ethnicity F
Caucasian/White n (%) 67 (89.3%) 71 (89.9%) 72 (91.1%) 61 (93.8%)
Black n (%) 2 (2.7%) 1 (1.3%) 3 (3.8%) 1 (1.5%)
Asian n (%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%)
Combination n (%) 3 (4.0%) 2 (2.5%) 3 (3.8%) 0 (0.0%)
Other n (%) 3 (4.0%) 4 (5.1%) 1 (1.3%) 3 (4.6%)
Country F
Belgium n (%) 28 (37.3%) 24 (30.4%) 25 (31.6%) 22 (33.8%)
France n (%) 26 (34.7%) 34 (43.0%) 33 (41.8%) 25 (38.5%)
Ireland n (%) 21 (28.0%) 21 (26.6%) 21 (26.6%) 18 (27.7%)
Order of birth F
First n (%) 28 (37.3%) 29 (36.7%) 34 (43.0%)

22 (33.8%)

Second n (%) 31 (41.3%) 34 (43.0%) 36 (45.6%) 27 (41.5%)
Third n (%) 14 (18.7%) 12 (15.2%) 6 (7.6%) 16 (24.6%)
>Third n (%) 2 (2.7%) 4 (5.1%) 3 (3.8%) 0 (0.0%)
Age at first visit, day W Median (min-max) 4 (0–28) 4 (0–28) 6 (0–28) 5 (0–28)
Gestational age, wk W Median (min-max) 39 (37–41) 40 (37–41) 40 (37–41) 39 (37–41)
Weight at birth, g T MeanSD 3336 429 3378 358 3370 368 3444 377
Length at birth, cm W Median (min-max) 50 (45–54) 50 (46–54) 50 (45–53) 50 (46–54)
Maternal age, yr T MeanSD 29.4 4.9 30.3 5.2 29.5 5.1 29.5 4.9
Maternal BMI, kg/m2 W Median (min-max) 24 (17–43) 24 (20–45) 25 (16–39) 25 (16–36)
Paternal age, yr T MeanSD 32.2 5.4 32.6 6.2 32.1 5.6 32.7 5.3
Paternal BMI, kg/m2 W Median (min-max) 25 (18–40) 26 (18–34) 26 (19–36) 26 (19–36)
BMI ¼ body mass index; 15% FERM ¼ infant formula consisting of 15% fermented infant formula; 50% FERM ¼ infant formula consisting of 50%
fermented infant formula; scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-oligosaccharides; SD ¼ standard deviation.
Values are significantly different. For the analysis of continuous data 2 sample t tests (T) were used and Wilcoxon rank sum tests (W) were used in case of
violation of normality assumption and/or presence of outliers. Categorical response parameters were analyzed by using Fisher exact tests (F).
JPGN  Volume 63, Number 4, October 2016 Fermented Infant Formulae With scGOS/lcFOS Support Adequate Growthdifferences in subject characteristics, including sex ratio, of the PP
intervention groups were observed, except for a higher number of
first-born infants in the scGOS/lcFOS with 50% FERM compared
with the 50% FERM only group (FE P¼ 0.014; Table 2), which is
considered to be a statistically significant difference by chance and
without clinical relevance. Baseline anthropometric measures were
not statistically different between treatment groups (Table 2).
Formula Consumption
The feeding history of subjects before the baseline visit,
(any) breast-feeding and/or type of formula feeding, was notTABLE 3. Average daily product intake (mL/day) during the intervention
scGOS/lcFOS (n¼ 75) scGOS/lcFOS þ15% FERM (n¼
Visit 2 (n) 699 124 (67) 685 131 (72)
Visit 3 (n) 772 109 (65) 768 140 (66)
Visit 4 (n) 827 151 (59) 817 139 (65)
Visit 5 (n) 852 123 (55) 859 128 (62)
Diaries were included in the analysis if product intake was recorded for at least
15% FERM ¼ infant formula consisting of 15% fermented infant formula; 5
scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-olig
www.jpgn.orgsignificantly different between groups in the PP population. In
general, all study formulae were well accepted by the
infants indicated by the high parental evaluation score (median
score of 9 on evaluation scale 1–10 for all formulae; data not
shown). The study product intake was not significantly different
between subjects of each intervention group throughout the study
(Table 3).
Infant Growth Patterns
In all comparisons of interest, the 2-sided 90% confidence
interval (CI) of the mean lay well within the predefined equivalentperiod of the per protocol population (means standard deviation)
79) scGOS/lcFOS þ50% FERM (n¼ 79) 50% FERM (n¼ 65)
697 111 (69) 728 129 (60)
782 161 (70) 825 155 (56)
830 129 (67) 867 159 (54)
878 137 (62) 928 159 (52)
3 days. The data were analyzed using a t test for each comparison of interest.
0% FERM ¼ infant formula consisting of 50% fermented infant formula;
osaccharides.
e47
–3 –2
scGOS/IcFOS + 50% FERM
vs scGOS/IcFOS
scGOS/IcFOS + 50% FERM
vs 50% FERM
scGOS/IcFOS + 15% FERM
vs scGOS/IcFOS
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FIGURE 2. Graphical display of the difference in means of the daily weight gain (g/d) equivalence analysis for the intervention group comparisons
of interest. The equivalence analysis was performed using parametric growth curves correcting for sex, site was taken into account as random
effect, and each subject’s intercept and slope taken into account as random effects. FERM¼ fermented infant formula; scGOS/lcFOS¼ short-chain
galacto-oligosaccarides and long-chain fructo-oligosaccharides.
Huet et al JPGN  Volume 63, Number 4, October 2016margins (Fig. 2), demonstrating equivalence in weight gain for the
PP population. Equivalence of weight gain per day for the same
comparison groups was also confirmed for the ITT population (data
not shown). Length gain, head circumference gain, and mid-upper
arm circumference gain during the study period were not different
between intervention groups in these 3 comparisons of interest
(Table 4). Moreover, in line with weight gain per day, equivalence
in length and head circumference gain per day during the inter-
vention period was demonstrated for these parameters in all but 1
comparison of interest. Equivalence could not be demonstrated for
the length gain of scGOS/lcFOS versus scGOS/lcFOSþ 50%
FERM groups in the PP population, with an apparently higher gain
in length in the latter group. In comparison with the WHO Growth
Standards based on growth of exclusively breastfed infants, the
mean z score values (including their 95% CI) for weight-for-age,
length-for-age, and weight-for-length in all intervention groups lay
within or close to the þ 0.5 to –0.5 range (Fig. 3).
(Serious) Adverse Events
The safety analysis was performed on the all-subjects-treated
population. In total, 28 serious AEs (SAE) were reported for 27
subjects (6.5%) during the entire study period. The prevalence of
SAEs was apparently higher in the scGOS/lcFOS group, but was only
significantly different from the scGOS/lcFOSþ 15% FERM group
(13.3% vs 2.7%, respectively; FE P¼ 0.007; Table 5). An initial
higher than expected rate of pyelonephritis was recorded in the
scGOS/lcFOS group. Assessing the medical records in more detail
revealed inconsistencies for the use of this medical term; 1 case was
found to be an urinary tract infection and 1 case a direct result of aTABLE 4. Average gain in infant growth, length, and head circumference (m
17 weeks) in the per protocol population
scGOS/lcFOS
(n¼ 75)
scGOS/lcF
Weight gain in g/day (n) 29.734 6.121 (57) 28.538
Length gain in mm/day (n) 1.078 0.195 (56) 1.078
Head circumference gain in mm/day (n) 0.572 0.128 (47) 0.559
15% FERM ¼ infant formula consisting of 15% fermented infant formula; 5
scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-olig
e48congenital anatomical anomaly causing vesicoureteral reflux,
reducing the incidence to the level of normal background incidence.
Only 3 SAEs were reported to be possibly (n¼ 2; reflux in scGOS/
lcFOSþ 50% FERM group and abdominal pain in 50% FERM
group) or probably (n¼ 1) related to the study products, the latter
being a possible case of cow’s milk allergy in the scGOS/
lcFOSþ 50% FERM intervention group. The rest of the SAEs were
‘‘unlikely to be related’’ or ‘‘not related’’ to the intake of the
intervention products. Overall, there was no safety concern. No
differences were observed in the frequency and type of AEs. The
most commonly observed (37%) were GI disorders (n¼ 154),
consisting mainly of abdominal pain, gastroesophageal reflux and
vomiting, and respiratory system disorders (n¼ 110; 26%), of which
rhinitis and upper respiratory tract infection were the most common.
Fecal Physiological and Microbial Parameters
After the intervention, that is, at 17 weeks of age, the
measured fecal physiological and microbial parameters of the
infants from the scGOS/lcFOS only arm confirmed its beneficial
effect (33), that is, lower pH, high relative amounts of acetate, low
relative levels of the other measured SCFAs, high occurrence of
measurable D- and L-lactate, high levels of SIgA and low occurrence
of C difficile, a taxonomic group known to be overrepresented in
formula-fed infants as compared to breast-fed infants (34) (Table 6).
No differences in fecal parameters were observed comparing both
scGOS/lcFOSþ 15% FERM and scGOS/lcFOSþ 50% FERM to
the scGOS/lcFOS only group, except for a higher pH in the scGOS/
lcFOSþ 50% FERM group (WR P¼ 0.028; Table 6). In contrast,
the fecal parameters of the infants from the 50% FERM only armean standard deviation) during the intervention period (baseline to
OS þ15% FERM
(n¼ 79)
scGOS/lcFOS þ50% FERM
(n¼ 79)
50% FERM
(n¼ 65)
 5.064 (65) 28.727 5.903 (64) 28.235 4.833 (52)
 0.180 (64) 1.135 0.127 (63) 1.092 0.147 (52)
 0.122 (54) 0.566 0.098 (52) 0.580 0.083 (42)
0% FERM ¼ infant formula consisting of 50% fermented infant formula;
osaccharides.
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FIGURE 3. Weight-for-age (upper), length-for-age (middle), and weight-for-length (lower) WHO z score: plot of predicted value plus 95%
confidence interval (CI) from mixed model analysis of z-score for the PP population per intervention group. FERM ¼ fermented infant formula;
scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-oligosaccharides.
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TABLE 5. Number and percentage of subjects with at least 1 serious adverse event presented by preferred term in the all subjects treated
population
n (%)
scGOS/lcFOS
(n¼ 98)
scGOS/lcFOS þ15% FERM
(n¼ 110)
scGOS/lcFOS þ50% FERM
(n¼ 106)
50% FERM
(n¼ 102)
Allergy 1 (0.9%)
Fever 1 (1.0%) 1 (0.9%) 1 (1.0%)
Pyloric stenosis 1 (1.0%) 1 (0.9%)
Abdominal pain 1 (1.0%)
Gastroesophageal reflux 1 (0.9%) 1 (1.0%)
Vomiting 2 (2.0%)
Fracture 1 (1.0%)
Urinary tract infection 1 (0.9%) 1 (1.0%)
Apnoea 1 (1.0%)
Bronchitis 1 (0.9%) 1 (0.9%)
Pneumonia 1 (0.9%) 1 (0.9%) 1 (1.0%)
Upper respiratory tract infection 2 (2.0%)
Surgery 1 (1.0%)
Varicella 1 (1.0%)
Pyelonephritis 3 (3.1%)

Total 13 (13.3%)y 3 (2.7%)y 7 (6.6%) 4 (3.9%)
15% FERM ¼ infant formula consisting of 15% fermented infant formula; 50% FERM ¼ infant formula consisting of 50% fermented infant formula;
scGOS/lcFOS ¼ short-chain galacto-oligosaccarides and long-chain fructo-oligosaccharides.
Although officially recorded as 3 cases of pyelonephritis, detailed assessment of the medical records revealed an inconsistency for the use of this medical
term, 1 case was a urinary tract infection and 1 case a direct result of a congenital anatomical anomaly causing vesicoureteral reflux.
yValues are significantly different, based on Fisher exact test (difference in number of subjects between groups).
Huet et al JPGN  Volume 63, Number 4, October 2016were always significantly different compared with the scGOS/
lcFOSþ 50% FERM group, with the exception of the SCFAs
acetate, propionate, and a tendency for higher butyrate levels in
the 50% FERM group (C P¼ 0.066; Table 6). The levels of fecal
calprotectin are in line with previously reported data from formula-
fed infants and no differences between groups were observed in the
comparisons of interest (Table 6; (35)).
DISCUSSION
To our knowledge, this is the first study evaluating the safety
of a partly fermented infant formula supplemented with prebiotics.
The primary outcome of the study is the demonstrated equivalence
in infant weight gain per day during the intervention period
analyzed according to both Intention to Treat and Per Protocol,
fulfilling the safety criteria of the American Academy of Pediatrics
(28). No differences in number and type of (serious) AEs were
observed. The obtained anthropometric measures in all intervention
groups were close to the WHO Growth Standards (mean z scores
within 0.5 SD), indicating that the formulae combining the
specific prebiotic mixture (scGOS/lcFOS 9:1) with fermented
infant formula support an adequate infant growth.
The current findings in the 50% FERM group confirm the
previously assessed adequate infant growth and tolerance based on
the long history of use (6) and based on the secondary anthropo-
metric outcomes of several studies which were smaller-scaled (10),
using a thickened fermented formula (8), or performed in older (9)
or preterm infants (36). Likewise, the outcomes of the present study
for the scGOS/lcFOS only intervention group confirm previous
findings indicating a normal infant growth (20–22). A meta-
analysis demonstrated a slightly increased weight gain (weight
gain increase of 0.97 g/day, 95% CI 0.24–1.70) but not length
or head circumference gain, in infants consuming a prebiotic-
containing formula (37). In the present study, we confirmed a small
increase (0.31 g/day) in mean weight gain per day during the
intervention period when prebiotics were added to a partly
fermented formula.e50All formulae were well accepted by parents and the presence
of the prebiotics and/or fermented formula did not affect formula
consumption. Only 1 SAE was found to be probably related to study
product intake, being an allergic reaction to cow’s milk experienced
in the scGOS/lcFOSþ 50% FERM group evidently relating to the
presence of dairy protein rather than fermented formula or pre-
biotics. The same intervention group contained 1 case of sympto-
matic gastroesophageal reflux indicated by the investigators to be
possibly related to the study product intake, as did the 50% FERM
intervention group. The overall prevalence of symptomatic gastro-
esophageal reflux was, however, low and also similar between
intervention groups. The percentage of infants with at least 1 SAE
was similar in all intervention groups with partly fermented
formula, but slightly higher in the scGOS/lcFOS only intervention
group, reaching statistical significance compared with the scGOS/
lcFOSþ 15%FERM intervention group. The observed number of
SAE in the scGOS/lcFOS group is, however, within the normal
range for an infant population and quite similar to the values
reported in comparable studies for (prebiotic) formula- or breast-
fed infants (38,39). Moreover, none of the SAEs in the scGOS/
lcFOS intervention group was indicated to be related to the product
and some rather the result of chance, for example, 4 of the 13 SAEs
were infants experiencing varicella, fracture, surgery, and pyloric
stenosis. Overall, the reported types of (serious) AEs are typical for
young infants and no difference in the frequency per type of
(serious) AEs was observed between the different formula groups.
Moreover, the drop-out rate and reasons for dropping out were
similar between intervention groups. Hence, there are no safety
concerns for use of products combining prebiotics and fermented
formula in healthy, term infants.
The presence of scGOS/lcFOS (9:1) in nonfermented infant
formula was found to modulate the microbiota of infants toward a
more ‘‘breast-fed like’’ composition with more bifidobacteria and
less pathogenic bacteria such as clostridia-related species
(16,18,20,31). This observed modulation in microbiota was found
to be associated with differences in metabolic activity of thewww.jpgn.org
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Huet et al JPGN  Volume 63, Number 4, October 2016microbiota resulting in a reduction in stool pH, an SCFA pattern
containing a higher proportion of acetate, a lower proportion of
propionate or other SCFAs, and increased levels of fecal SIgA
(16,20,31). The present study confirms this established bifidogenic
effect of scGOS/lcFOS (9:1) when added to partly fermented
formulae, indicated by the lower percentage of C difficile, the higher
occurrence of measurable lactate levels, the decreased pH, and
increased SIgA levels reported for the scGOS/lcFOSþ 50% FERM
group compared with the 50% FERM only group. Moreover, no
differences in fecal parameters were demonstrated between the
formulae containing scGOS/lcFOS (9:1), irrespective of the presence
or dosage of fermented formula (scGOS/lcFOSþ 15% FERM and
scGOS/lcFOSþ 50% FERM vs scGOS/lcFOS only). Hence, the
present study reconfirms the beneficial effect of scGOS/lcFOS,
which was not affected by the presence of fermented formula.
In conclusion, a partly fermented formula containing a
specific mixture of prebiotics supports adequate growth in early
life firstly based on the weight gain equivalence between interven-
tion groups in the ITT and PP populations and, secondly, on the
similarity in growth development compared to the WHO growth
standards. In addition, these formulae were well-tolerated and safe
based on growth and AE outcomes. As a next step, the potential
effect of partly fermented formulae with scGOS/lcFOS on GI
function is under investigation.
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